average weight loss on glp 1 first month Rx Trends: Real-World Data GLP-1s for How Much Weight Can You

Check the latest B2B trends and request your price quote now to maximize cost efficiency and supply reliability

The dual GIP/GLP-1 receptor agonist tirzepatide has already been approved and other dual receptor agonists are expected soon

Mounjaro and other GLP-1s should be avoided or used only under close supervision by people with a history of pancreatitis, gallstones, medullary thyroid cancer or MEN2, severe kidney disease, a very low BMI or eating disorder, and during pregnancy or breastfeeding

Trusting the process and understanding these realistic timelines can save you a lot of unnecessary frustration

To maximize results, choose liposomal versions of both to ensure they survive the digestive process

Dhillon, S., & Semaglutide (2018)